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Optimalmanagementof neuropathic pain is amajor clinical challenge.We investigated the involvementof c-JunN-terminal kinase (JNK)
in neuropathic pain produced by spinal nerve ligation (SNL) (L5). SNL induced a slow (3 d) and persistent (21 d) activation of JNK,
in particular JNK1, in GFAP-expressing astrocytes in the spinal cord. In contrast, p38 mitogen-activated protein kinase activation was
found in spinalmicroglia after SNL,which had fallen to near basal level by 21 d. Intrathecal infusion of a JNKpeptide inhibitor, D-JNKI-1,
did not affect normal pain responses but potently prevented and reversed SNL-induced mechanical allodynia, a major symptom of
neuropathic pain. Intrathecal D-JNKI-1 also suppressed SNL-induced phosphorylation of the JNK substrate, c-Jun, in spinal astrocytes.
However, SNL-induced upregulation of GFAP was not attenuated by spinal D-JNKI-1 infusion. Furthermore, SNL induced a rapid
(12 h) but transient activation of JNK in the L5 (injured) but not L4 (intact) DRG. JNK activation in the DRG was mainly found in
small-sized C-fiber neurons. Infusion of D-JNKI-1 into the L5 DRG prevented but did not reverse SNL-induced mechanical allodynia.
Finally, intrathecal administration of an astroglial toxin, L--aminoadipate, reversed mechanical allodynia. Our data suggest that JNK
activation in the DRG and spinal cord play distinct roles in regulating the development and maintenance of neuropathic pain, respec-
tively, and that spinal astrocytes contribute importantly to the persistence of mechanical allodynia. Targeting the JNK pathway in spinal
astroglia may present a new and efficient way to treat neuropathic pain symptoms.
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Introduction
Damage to peripheral nerve very often results in neuropathic
pain. Current treatments for this pain are only partially effective,
and additional development is hindered by our incomplete
knowledge of how neuropathic pain is induced and maintained.
Increasing evidence shows that mitogen-activated protein ki-
nases (MAPKs) play important roles in the induction and main-
tenance of chronic pain (for review, see Ji andWoolf, 2001; Ji and
Strichartz, 2004; Obata and Noguchi, 2004). The MAPK family
has three major members, extracellular signal-regulated kinase
(ERK), p38, and c-Jun N-terminal kinase (JNK), representing
three different signal transduction pathways. Compared with
well documented roles of p38 and ERK in neuropathic pain, the
distinct role of JNK in dorsal root ganglion (DRG) and spinal
cord has not been investigated.
JNK contributes importantly to stress-induced apoptosis in
various cell types (Xia et al., 1995; Borsello et al., 2003). For
example, cerebral ischemia activates JNK, leading to excitotoxic
neuronal death (Borsello et al., 2003). Recently, a cell-penetrating
and proteinase-resistant peptide inhibitor of JNK (D-JNKI-1),
derived from the JNK binding domain of JNK-interacting
protein-1, was developed to competitively inhibit JNK binding to
its substrates.D-JNKI-1 is an extremely effective neuroprotectant
in vitro against excitotoxicity of cortical neurons and in vivo
against two models of focal cerebral ischemia (Borsello et al.,
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2003; Borsello and Bonny, 2004), as well as in other neurodegen-
erative paradigms (Wang et al., 2003; Tezel et al., 2004).
Studies on pain research focus primarily onneuronal cells; less
is known about the importance of glial cells. However, accumu-
lating evidence indicates that spinal glia contribute to the patho-
genesis of pain (DeLeo and Yezierski, 2001; Watkins et al., 2001;
Tsuda et al., 2005). Bothmicroglia and astrocytes are activated in
the spinal cord after nerve injury (Jin et al., 2003; Raghavendra et
al., 2003). Glial cells not only express various receptors for neu-
rotransmitters but, on activation, also produce multiple inflam-
matory mediators [e.g., interleukin-1 (IL-1), IL-6, tumor ne-
crosis factor- (TNF-), and prostaglandin E2 (PGE2)] that are
implicated in pain sensitization (Watkins et al., 2001; Watkins
and Maier, 2003; DeLeo et al., 2004; Ji and Strichartz, 2004).
Increasing evidence suggests that spinal microglia are essential to
the initial development of neuropathic pain (Abbadie et al., 2003;
Jin et al., 2003; Raghavendra et al., 2003; Tsuda et al., 2003, 2005;
Coull et al., 2005; Tanga et al., 2005). Although astroglia are
persistently activated in the spinal cord after nerve injury
(Honore et al., 2000), the participation of this glial subtype in
pain sensitization remains essentially unknown.
Here, we demonstrate another powerful but different role of
JNK for controlling neuropathic pain. We report that JNK is
activated in both DRG and spinal cord in a neuropathic pain
condition produced by ligation of the L5 spinal nerve. Whereas
transient activation of JNK in DRG neurons is involved in the
induction of neuropathic pain, persistent activation of JNK in
spinal astrocytes appears critical for the maintenance of neuro-
pathic pain. In particular, D-JNKI-1 can effectively block me-
chanical allodynia, a characteristic behavioral response for neu-
ropathic pain. Furthermore, an astroglial toxin administered in
spinal fluid potently attenuates established neuropathic pain.
Materials andMethods
Animals and surgery. Male adult Sprague Dawley rats (220–260 g) were
used under Harvard Medical School Animal Care institutional guide-
lines. To produce a spinal nerve ligation (SNL), under pentobarbital
anesthesia (40–50mg/kg, i.p.), the L5 transverse process was removed to
expose the L4 and L5 spinal nerves. The L5 spinal nerve was then isolated
and tightly ligated with 6-0 silk thread (Kim and Chung, 1992).
Drug administration. The peptide JNK inhibitor was synthesized by
linking the 10 amino acid human immunodeficiency virus Tat (48–57)
transporter sequence to a 20 amino acid JNK-binding motif (JBD20) of
JNK-interacting protein-1/islet-brain 1. The peptide was also synthe-
sized as protease-resistant D-form to expand its half-life in vivo (Borsello
et al., 2003). A peptide with Tat sequence but lacking JBD20 was used as
the control. The peptide inhibitor is highly selective and does not affect
the activity of 40 other protein kinases (Borsello et al., 2003). The small
chemical JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one)
and the astroglial toxin L--aminoadipate (L--AA) were purchased
fromCalbiochem (La Jolla, CA) and Sigma (St. Louis,MO), respectively.
For sustained drug infusion, laminectomy was performed at the
spinal level, 2 cm below the lumbar enlargement, and a polyethylene
(PE5) catheter was implanted into the intrathecal space of the spinal
cord, ending at spinal L4–L5 level. The catheter was connected to an
osmotic pump (Alzet, Cupertino, CA) for drug infusion. The drug-
filled pumps were soaked in saline for 3 h before implantation and
placed subcutaneously on the back of rats (Ji et al., 2002a,b). For drug
infusion into the DRG, a PE5 catheter was inserted into the L5 spinal
nerve and threaded toward to the L5 DRG either 30 min before or 10 d
after the ligation of the same spinal nerve (L5). For single intrathecal
injection, spinal cord puncture was made under brief sevofluorane
anesthesia with a 27 gauge needle between the L5 and L6 level to
deliver the reagents (20 l) to the CSF (Zhuang et al., 2005). Imme-
diately after the needle entry into subarachnoid space (change in
resistance), a brisk tail flick could be observed.
Figure 1. a–l, SNL induces persistent JNK activation in spinal astroglia. a, b, Immunohisto-
chemistry reveals increases in pJNK levels in the ipsilateral spinal dorsal horn (L5) 10d after SNL.
White lines indicate the border of the dorsal horn gray matter. Scale bar, 50m. c, d, High-
magnification images from a and b, respectively, showing pJNK staining in themedial superfi-
cial dorsal horn. Scale bar, 50 m. e, Double immunofluorescence shows that pJNK (red) is
completely colocalizedwith astrogliamarker GFAP (green) in themedial superficial dorsal horn.
Two single-stained images were merged. e has the same magnification as c. f, High-
magnification image from e demonstrating the colocalization of pJNK and GFAP. Scale bar, 25
m. g, h, SNL also induces JNK activation in the dorsal horn after 3 weeks. Scale bar, 25m. i,
Colocalization of pJNK (i) and GFAP (i) in the superficial dorsal horn 21 d after SNL. i is the
merge of i and i. Scale bar, 25m. j, Time course of pJNK induction in the L5 spinal cord after
SNL, as indicated by the number of pJNK-IR cells in the superficial dorsal horn (laminas I–III).
**p  0.01 by ANOVA compared with control (n  3 and 4). k, l, SNL induces persistent
activation of astrocytes in the dorsal horn after 3 weeks, as indicated by GFAP upregulation.
Scale bar, 50m.
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Western blots. As described previously (Zhuang et al., 2005), animals
were rapidly killed, and the L5 spinal segments (dorsal part) were quickly
removed and homogenized in a SDS sample buffer containing a mixture
of proteinase and phosphatase inhibitors (Sigma). Protein samples (30
g) were separated on SDS-PAGE gel and transferred to polyvinylidene
difluoride blots. The blots were blocked with 5% milk and incubated
overnight at 4°C with antibody against phosphorylated JNK (pJNK) or
JNK (anti-rabbit, 1:1000; Cell Signaling Technology, Beverly, MA).
These blots were further incubated with HRP-conjugated secondary an-
tibody, developed in ECL solution, and exposed onto Hyperfilm (Amer-
sham Biosciences, Arlington Heights, IL).
Immunohistochemistry. Animals were terminally anesthetized with
isoflurane and perfused through the ascending aorta with saline followed
by 4%paraformaldehyde/1.5%picric acid. After the perfusion, the spinal
cord segments (L5) and the DRGs (L4, L5) were removed and postfixed
in the same fixative overnight. Spinal sections (transverse, free-floating,
30 m) and DRG sections (15 m) were cut in a cryostat and processed
for immunofluorescence (Ji et al., 1995; Jin et al., 2003). All of the sec-
tions were blocked with 2% goat serum in 0.3% Triton X-100 for 1 h at
room temperature (RT) and incubated overnight at 4°C with anti-pJNK
antibody (anti-rabbit, 1:1000; Cell Signaling Technology). The sections
were then incubated for 1 h at RT with cyanine 3-conjugated secondary
antibody (1:400; Jackson ImmunoResearch,
West Grove, PA). Other primary antibodies
used in this study were polyclonal antibodies
for JNK1 (rabbit, 1:2000; Santa Cruz Biotech-
nology, Santa Cruz, CA), pERK, p-p38, p-c-Jun
(rabbit, 1:500, phosphorylated forms; Cell Sig-
naling Technology), and monoclonal antibod-
ies for neuronal-specific nuclear protein
(NeuN) (mouse, 1:5000; Chemicon, Temecula,
CA), glial fibrillary acidic protein (GFAP)
(mouse, 1:5000; Chemicon), and neurofila-
ment 200 kDa (NF-200) (mouse, 1:5000;
Sigma). For double immunofluorescence, sec-
tions were incubated with a mixture of two pri-
mary antibodies (monoclonal and polyclonal),
followed by a mixture of the two respective sec-
ondary antibodies. The specificity of the stain-
ing was tested by omission of primary antibod-
ies or absorption with peptide antigens. Stained
sections were examined with a Nikon (Tokyo,
Japan(fluorescence microscope, and images
were captured with a CCD Spot camera.
Behavioral analysis. Animals were habituated to the testing environ-
ment daily for 3–7 d before baseline testing. For testing mechanical sen-
sitivity, animals were put under inverted plastic boxes (11 13 24 cm)
on an elevatedmesh floor and allowed 30min for habituation, before the
threshold testing.Mechanical allodyniawas tested using von Frey hairs in
a blinded manner. The paw was pressed with one of a series of von Frey
hairs with logarithmically incrementing stiffness (0.6, 1, 1.4, 2, 4, 6, 8, 10,
15, and 26 g) (Stoelting, Kiel,WI), presented perpendicular to the plantar
surface (5–6 s for each hair). The 50% withdrawal threshold was deter-
mined using Dixon’s up–down method (Chaplan et al., 1994).
Quantification and statistics. To quantify positive cell profiles in the
spinal cord, five to eight sections from the L5 spinal cord segments were
randomly selected. An image in a square (450 338 m) on the medial
two-thirds of the superficial dorsal horn (laminas I–III), as described
previously byMolander et al. (1984), was captured under 20 objective,
and all of the positively stained cells in the area were counted by an
investigator who did not know the treatment. Those cells with distinct
contrast to the background were scored as positive. Background levels
were obtained from sections incubated without primary antibody.
Roughly, the densities of these positive cells should exhibit a signal/back-
ground ratio2. This counting does not determine the total numbers of
cells (Coggeshall and Lekan, 1996). Instead, it provides a comparison to
evaluate differences between control and treated animals. To quantify
pJNK expression in the DRG, the percentages of pJNK-positive neurons
in the L5 and L4 DRG from four nonadjacent sections were determined
as described previously (Ji et al., 1996). Data were presented as mean
SEM. Differences between groups were compared using Student’s t test
or ANOVA, followed by Fisher’s PLSD test. The criterion for statistical
significance was p 0.05.
Results
Activation of JNK in the spinal astrocytes after nerve injury
SNL produced rapidly appearing (1 d) and persistent (3
weeks) neuropathic pain (Kim and Chung, 1992). SNL also in-
duced a marked activation of JNK in the spinal cord. Many more
pJNK (active form of JNK)-immunoreactive (IR) cells were
found in the ipsilateral than the contralateral spinal cord, pre-
dominantly in the superficial dorsal horn (laminas I–III) on day
10 (Fig. 1a–d) and day 21 (Fig. 1g,h). Double immunofluores-
cence indicated that pJNK was completely colocalized with
GFAP, a marker for astrocytes, in the spinal cord at different
times (days 3–21) of neuropathic pain development (Fig. 1e,f, i).
To determine the percentage of cells that showed pJNK/GFAP
double labeling, we quantified the number of pJNK and GFAP
single-stained cells, as well as pJNK/GFAP double-stained cells in
themedial laminas I–III (seeMaterials andMethods) in six spinal
Figure2. a–e, JNK1 is activated in spinal astrocytes.a,Western blot analysis reveals an increase in the level of pJNK1 (46 kDa)
in the L5 spinal cord 10 d after L5 SNL. b, Immunohistochemistry shows JNK1 expression in themedial superficial spinal cord 10 d
after SNL. Scale bar, 20m. c– e, High-magnification images reveal double staining between JNK1 (red) andNeuN (c), OX-42 (d),
or GFAP (e). Two single-stained images were merged. Scale bar, 10m. Note that the JNK1 is only colocalized with GFAP.
Figure 3. a–d, SNL induces phosphorylation of c-Jun in spinal astroglia. a, b, Immunohis-
tochemistry shows increases in p-c-Jun levels in the ipsilateral spinal dorsal horn (L5) 10 d after
SNL.White lines indicate theborder of thedorsal horngraymatter. Scalebar, 100m. c, Double
immunofluorescence shows that p-c-Jun (red) is completely colocalized with astroglia marker
GFAP (green) in the medial superficial dorsal horn. Scale bar, 50 m. d, High-magnification
image demonstrating the colocalization of pJNK and GFAP. Two single-stained images were
merged. Note that p-c-Jun is expressed in the nucleus of GFAP-labeled cells. Scale bar, 10m.
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sections from three different rats perfused
10 d after SNL. Approximately 99% of
pJNK-IR cells (358 of 363) were also
GFAP-IR, suggesting that pJNK is almost
exclusively expressed in astrocytes. How-
ever, only 33% of GFAP-IR cells (358 of
1080) were pJNK-IR, indicating that JNK
is only activated in a fraction of spinal
astrocytes.
A time course study showed that pJNK
elevation was not evident at day 1, when
symptoms of neuropathic pain began to
develop (Fig. 1j). The rise in pJNK levels
was significant on day 3, reached a peak on
day 10, and remained at high levels on day
21 after SNL (Fig. 1j). Consistently, SNL
induced a persistent upregulation ofGFAP
in the dorsal horn. GFAP expression re-
mained at high level on day 21 (Fig. 1k,l).
Activation of JNK1 and c-Jun in spinal
astrocytes after nerve injury
Western blot analysis confirmed an in-
crease in spinal pJNK after SNL. Although
both JNK1 (46 kDa) and JNK2 (54 kDa)
were constitutively expressed in the spinal
cord, only JNK1 was phosphorylated in
the spinal cord (Fig. 2a). There was no sig-
nificant change in pJNK expression after sham surgery (Fig. 2a).
Double immunofluorescence showed that JNK1 was colocalized
with GFAP but not withNeuN (neuronalmarker) or withOX-42
(an antibody for themicroglial marker CD11b) in the spinal cord
after SNL (Fig. 2b–e). Therefore, JNK1 appears to be the isoform
that is phosphorylated, exclusively in spinal astrocytes.
The transcription factor c-Jun is the best known substrate of
JNK. JNK is known to activate p-c-Jun. SNL also induced an
upregulation of p-c-Jun in the ipsilateral spinal cord (Fig. 3).
Interestingly, p-c-Jun was also localized in GFAP-expressing as-
trocytes in the dorsal horn, with predominant localization in the
nucleus (Fig. 3).
Activation of p38MAPK in spinal microglia after nerve injury
To determine whether different MAPKs show different activa-
tion patterns after nerve injury, we also examined the activation
of p38 MAPK in the spinal cord after SNL. As shown previously
(Jin et al., 2003), SNL strongly activated p38 inOX-42-expressing
spinal microglia on day 3 (Fig. 4a–c). The number of p-p38-IR
cells remained elevated in the ipsilateral spinal cord at 21 d after
SNL but had markedly declined from the peak, and the p-p38 at
this time was primarily localized in the nucleus of microglia (Fig.
4d–f). In parallel, microglial activation wasmaximal on day 3 but
had fallen by day 21, although not to basal levels, as indicated by
OX-42 staining (Fig. 4g–j).
Prevention and reversal of neuropathic pain by intrathecal
infusion of JNK inhibitors
SNL-induced neuropathic pain is characterized by mechanical
allodynia (pain-like response to preinjury innocuousmechanical
stimulation) (Kim and Chung, 1992). To determine whether spi-
nal JNK activation has a role in the development of mechanical
allodynia, we infused the peptide inhibitor D-JNKI-1 via an os-
motic pump for 2 weeks, starting 3 d before SNL. Although in-
trathecal infusion of D-JNKI-1 to spinal fluid did not change
basal mechanical threshold tested before nerve injury, it pre-
vented the development of mechanical allodynia for10 d (Fig.
5). However, neuropathic pain was not permanently prevented,
because allodynia developed again once the 2 week infusion
ended (Fig. 5).
To investigate whether JNK inhibition would reverse estab-
lished neuropathic pain, a treatmentmodemore relevant to clin-
ical situation, we infused the peptide inhibitor intrathecally via an
osmotic pump 10 d after establishment of SNL-induced allo-
dynia. This treatment (3 d infusion) effectively reversed SNL-
induced allodynia for4 d (Fig. 6a).
To test the effects of a single bolus injection of JNK inhibitors
on SNL-induced allodynia, we injected D-JNKI-1 and the small-
molecule JNK inhibitor SP600125 intrathecally on post-SNL day
10. Both inhibitors could reversemechanical allodynia for 6–12 h
(Fig. 6b) in a dose-dependentmanner (Fig. 6c). A control peptide
(with Tat sequence but lacking the JBD20 sequence) had no effect
Figure4. a–j, SNL activates p38MAPK in spinalmicroglia.a–f, p-p38 immunofluorescence in the dorsal horn of the ipsilateral
(Ipsi; a, c, d, f ) and contralateral (Contra; b, e) side at 3 d (a– c) and 21 d (d–f ) after SNL. c and d are double staining for p-p38
(red) and OX-42 (green). Note that p-p38 is expressed in OX-42-IR microglia at 3 and 21 d. Two single-stained images were
merged. Scale bars: b, e, 100m; c, f, 50m. The asterisk indicates an artifact. g–j, OX-42 immunofluorescence in the dorsal
horn of the ipsilateral (g, i) and contralateral (h, j) side at 3 d (g, h) and 21 d (i, j) after SNL. Scale bar, 100m.
Figure 5. Intrathecal perfusion of D-JNKI-1 prevents the development of neuropathic pain.
The peptide JNK inhibitor D-JNKI-1 (50M) was infused into intrathecal space via an osmotic
pump (0.5l/h for 2weeks), starting 3 d before SNL. Note that the basalmechanical sensitivity
is not changed after D-JNKI-1 infusion. The inhibitor almost completely blocks allodynia for
10 d, but neuropathic pain returns after infusion stops. *p 0.05, **p 0.01 by t test
compared with corresponding vehicle controls (saline); n 6.
3554 • J. Neurosci., March 29, 2006 • 26(13):3551–3560 Zhuang et al. • JNK, Spinal Astrocytes, and Neuropathic Pain
(Fig. 6c). We also found that D-JNKI-1 was 50 times more
potent than SP600125 in this reversal (Fig. 6c), the ED50 values
being 0.3 and 14.9 nmol, respectively (Fig. 6d).
Regulation of c-Jun phosphorylation but not GFAP
expression in astrocytes by JNK
To explore the mechanisms by which JNK activation would me-
diate neuropathic pain, we examined the effect of D-JNKI-1 on
SNL-induced phosphorylation of c-Jun. Intrathecal infusion of
D-JNKI-1, at a concentration that fully reversed allodynia (Fig.
6a), significantly suppressed SNL-induced c-Jun phosphoryla-
tion in spinal astrocytes (Fig. 7a). This suppression was only par-
tial because of the fact that there were more p-c-Jun-IR cells than
pJNK-IR cells in the spinal cord after SNL (Figs. 1j, 7a). There-
fore, c-Jun phosphorylation in some cells may not be caused by
pJNK.
SNL also induced a doubling of GFAP-
expressing astrocytes in the spinal cord on
day 10 (Fig. 7b). Astrocytes in cords from
uninjured rats were in the resting state, ex-
hibiting long and thin processes. After
nerve injury, spinal astrocytes became re-
active, demonstrating larger cell bodies
and thicker processes. Although pJNKwas
colocalized with GFAP (Fig. 1), D-JNKI-1,
at a concentration sufficient to reverse al-
lodynia, did not change either the number
of GFAP-expressing astrocytes (Fig. 7b) or
the reactive morphology of astrocytes
(data not shown).
Uptake of D-JNKI-1 by DRG cells after
intrathecal injection
Although the intrathecal route is tradi-
tionally believed to target spinal cells, in-
trathecal injection ofMAPK inhibitors has
also been shown to affect DRG cells (Ji et
al., 2002b;Obata et al., 2004a). To examine
whether a larger peptide inhibitor can dif-
fuse to and be taken up by DRG cells, we
intrathecally injected a cumarin-labeled
Tat peptide (4 nmol). Many fluorescence-
labeled neurons and satellite cells were
found in the DRG 3 h after the injection
(Fig. 8), indicating that the peptide inhib-
itor is taken up byDRG cells after intrathe-
cal injection.
JNK activation in the injured
small-sized neurons of the DRG
Because intrathecal D-JNKI-1 could also act on DRG cells, we
further examined JNK activation in the DRG after nerve ligation.
A previous study reported increased pJNK expression in DRG
neurons 1 week after nerve injury (Obata et al., 2004a). However,
we found amuch earlier induction of pJNK in theDRGafter SNL.
In contrast to the kinetics in the spinal cord (Fig. 1j), the peak of
pJNK induction in sensory neurons of the injured L5DRGwas at
12 h. At this time point, 35% of DRG neurons showed pJNK
expression, whereas only 5% of neurons were positive in naive
rats (Fig. 9a–c). There was only a modest increase of pJNK in the
L5 DRG at 6 h after nerve injury (data not shown). Double stain-
ing indicated that pJNK was rarely colocalized with NF-200, a
marker for large myelinated neurons, indicating that pJNK is
mainly induced in C-type neurons (with C-fibers) in the L5 DRG
after SNL (Fig. 9d). However, JNK activation in the L5 DRG was
significantly reduced 10 d after SNL (Fig. 9c,e). Indeed, there are
notmany pJNK-IR neurons in the L5DRG even 1week after SNL
(Obata et al., 2004a).
Nerve injury has been known to produce changes not only in
the injured neurons but also in the non-injured neurons that are
adjacent to the injured neurons. For example, SNL (L5) induces
p38 activation in the intact L4 DRG (Obata et al., 2004a,b). In
contrast, pJNK was not induced in the L4 DRG (Fig. 9c,f), nor
was pJNK induced in the L5DRGof sham-operated rats (data not
shown). These data suggest that axonal injury is required for JNK
activation in sensory neurons.
SNL also induced very dramatic upregulation of p-c-Jun in
the nucleus of the injured (L5) but not the intact (L4) DRG (Fig.
9g,h). However, the percentage of p-c-Jun-IR neurons was much
Figure 6. a–d, Intrathecal administration of JNK inhibitors reverses neuropathic pain. a, Reversal of SNL-inducedmechanical
allodynia by intrathecal infusion of D-JNKI-1 (50M) via an osmotic pump (0.5l/h for 3 d) starting on post-SNL day 10. *p
0.05 by t test compared with corresponding saline controls; n 5. b, Reversal of SNL-induced mechanical allodynia by a bolus
intrathecal injection of D-JNKI-1 (4 nmol) and SP600125 (50 nmol) at post-SNL day 10. *p 0.05, **p 0.01 by ANOVA
comparedwith correspondingpreinjectionbaseline;n6. c, Effects ofD-JNKI-1 (0.2 and4nmol) and its control peptide (4nmol),
SP600125 (SP; 50 and 150 nmol) and its vehicle (20%DMSO), and saline, via intrathecal bolus injection, onmechanical allodynia
on post-SNL day 10. **p 0.01 compared with the vehicle (Veh); ##p 0.01, compared with the control peptide; n 6. The
mechanical allodynia was tested at 3 h after all of the injections. d, Dose-dependent effects of D-JNKI-1 and SP600125, intrathe-
cally injected on day 10, on reversingmechanical allodynia. Mechanical allodynia was tested 3 h after the injections. The ED50 for
D-JNKI-1 and SP600125 is 0.3 and 14.9 nmol, respectively (n 6).
Figure 7. a, b, Effects of intrathecal D-JNKI-1 on SNL-induced c-Jun phosphorylation and
GFAPexpression in astrocytes. Thenumbers of p-c-Jun-IR (a) andGFAP-IR (b) cells in themedial
two-thirds of superficial dorsal horn (laminas I–III) at 10 d after SNL were quantified. D-JNKI-1
was intrathecally infused via an osmotic pump (0.5l/h, 50M) at 7 d after SNL, and animals
were perfused 3 d after the infusion. **p 0.01, compared with controls; p 0.05, com-
pared with SNL, ANOVA; n 4.
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higher than that of pJNK-IR neurons:80%of neurons in the L5
DRG expressed p-c-Jun 12 h after SNL (Fig. 9h). This percentage
could be even higher, because not every neuronal profile captures
nucleus in 15-m-thick DRG sections.
Prevention but not reversal of neuropathic pain by DRG
perfusion of D-JNKI-1
To examine the role of JNK activation in the DRG for neuro-
pathic pain, we directly infused D-JNKI-1 to the L5 DRG by
inserting a PE5 catheter inside the L5 spinal nerve close to the
DRG. Perfusion of the L5 DRG with D-JNKI-1 completely pre-
vented the development of SNL-induced mechanical allodynia
for more than 1 week (Fig. 10a). Mechanical allodynia matched
that of untreated rats on post-SNL day 11 when no drug was left
in the osmotic pump (Fig. 10a). In contrast to intrathecal infu-
sion, perfusion of D-JNKI-1 into the L5 DRG 10 d after SNL did
not reverse established allodynia (Fig. 10b). Together, our data
suggest that JNK activation in small-sized (C-type) neurons of
the L5DRG is required for the induction but not themaintenance
of mechanical allodynia after nerve injury.
Reversal of neuropathic pain by an astroglial toxin
L--AA is a cytotoxin relatively specific for
astrocytes. Ultrastructural evidence sug-
gests that degeneration is confined to as-
trocytes after the injection of this toxin
into the striatum (Huck et al., 1984; Khur-
gel et al., 1996; Rodriguez et al., 2004). To
further examine whether spinal astrocytes
are important for neuropathic pain,we ad-
ministrated L--AA intrathecally to SNL
rats on postoperative day 10. SNL-induced
mechanical allodynia was suppressed by
L--AA at 3, 6, 24, and 48 h after the injec-
tion, in a dose-dependent manner (Fig.
11a). The anti-allodynic effects of L--AA
were reversible, recovering after 3 d (Fig.
11a). In agreement with previous studies
(Khurgel et al., 1996; Rodriguez et al.,
2004), L--AA (50 nmol) produced a
marked reduction of GFAP-positive astro-
cytes in the dorsal horn (Fig. 11b,c).
L--AA also decreased the expression of
JNK1 (d, e), which was also expressed in
spinal astrocytes. However, L--AA did
not affect the number of NeuN-positive
neurons in the spinal cord (Fig. 11d,e), in
support of previous studies (Khurgel et al.,
1996; Rodriguez et al., 2004), nor did
L--AA alter the basal pain sensitivity in
uninjured animals even at a high dose (150
nmol); the mechanical threshold was
15.7  2.5, 16.0  4.1, and 15.4  2.8 g
before and at 6 and 24 h after intrathecal
L--AA injection (150 nmol), respectively
( p 0.05; n 5).
Discussion
This study has revealed new mechanisms
for neuropathic pain development and maintenance. We have
several major findings in this study. First, we have shown that
SNL rapidly (12 h) but transiently (10 d) activates JNK in
small-sized (C-type) neurons of the injured (L5) DRG, which is
important for the induction/development but not the mainte-
nance of neuropathic pain. Second, we have demonstrated that
SNL slowly (3 d) but persistently (21 d) activates JNK in
spinal astrocytes, in which it is essential for the maintenance of
Figure 8. Uptake of the Tat peptide by DRG cells after intrathecal injection. Many
fluorescence-labeled neurons and satellite cells are present in the DRG 3 h after intrathecal
injection of a cumarin-labeled Tat peptide (4 nmol). Large and small arrows indicate neurons
and satellite cells, respectively. Scale bar, 50m.
Figure9. a–i, SNLinducesrapidbuttransientJNKactivationintheinjured(L5)neuronsoftheDRG.a,b,SNLproducesarapid(at12h)
pJNKincreaseinsmall-sizedneuronsoftheL5DRG.c,PercentageofpJNK-positiveneuronalprofiles intheL5andL4DRGsatdifferenttimes
afterSNL.**p0.01byANOVAcomparedwithcontrol (naive);n4.d,Double immunofluorescenceofpJNK(red)andNF-200 (green)
in the L5DRG.Note that pJNK is barely colocalizedwithNF-200.e, f, There is only low level of pJNKexpression in the L5DRGonday10 (e)
and in the L4DRGonday 0.5 (f ) after SNL.g–i, SNL induces p-c-Jun in the L5DRG (h) but not in the L4DRG (i). Scale bar, 50m.
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neuropathic pain. The role of spinal astrocytes in maintaining
neuropathic pain is further supported by our data showing rever-
sal of mechanical allodynia after intrathecal infusion of an astro-
glial toxin. Third, we have shown that different MAPKs (p38 and
JNK) are activated in different cell types (microglia and astro-
cytes), respectively, in the spinal cord after nerve injury.
JNK activation in the spinal cord and neuropathic pain
Our data show that JNK is slowly and persistently activated in
spinal astroglia after SNL. JNK activationwas also found in spinal
astrocytes after amyotrophic lateral sclerosis (Migheli et al.,
1997). Furthermore, JNK activation has been shown in spinal
astrocytes after partial sciatic nerve lesion, but only one time
point (21 d) was examined in this study (Ma and Quirion, 2002).
It is important to investigate the cellular localization of pJNK at
different times, because our previous studies have shown that
ERK is activated in different cell types (microglia vs astrocytes) in
the spinal cord at different times after nerve injury (Zhuang et al.,
2005).
It is of particular interest that different MAPKs exhibit differ-
ent activation patterns in the spinal cord after nerve injury.
Whereas JNK is persistently activated in spinal astrocytes, p38
appears to be transiently activated in spinal microglia, with the
peak activation in the first week (Table 1). Conversely, ERK acti-
vation is more dynamic; it is activated in spinal microglia in the
first week after nerve injury, but only in spinal astrocytes at late
times of nerve injury (Zhuang et al., 2005) (Table 1).
JNK has three isoforms: JNK1, JNK2, and JNK3. Whereas
JNK3 is expressed in brain neurons, JNK1 is expressed in non-
neuronal cells (e.g., immune cells) (Ip andDavis 1998; Borsello et
al., 2003; Kuan et al., 2003). Our data have shown that JNK1 is the
isoform that is activated in spinal astrocytes after SNL, because
(1) only JNK1 was hyperphosphorylated in the spinal cord after
SNL, and (2) JNK1 was expressed in spinal astrocytes in both
injured and non-injured side of the spinal cord.
Our results demonstrate that intrathecal administration of
JNK inhibitors, before or 10 d after nerve injury, prevented or
reversed SNL-induced mechanical allodynia. The peptide inhib-
itor D-JNKI-1 was more potent than the small-molecule inhibi-
tor SP600125, producing complete inhibition of SNL-induced
allodynia at lower concentrations. Although it is generally be-
lieved that intrathecal drug infusion should target spinal cells, it is
often neglected that the intrathecal route may also affect DRG
cells. We found that D-JNKI-1 was taken up by many DRG cells
after intrathecal injection. Therefore, the anti-allodynic effect of
intrathecal D-JNKI-1 could be mediated by JNK activation at
both DRG and spinal levels.
JNK activation in the DRG and neuropathic pain
We found that SNL activates JNK in the injured L5 DRG, in
support of a previous study (Obata et al., 2004a). However, peak
activation of JNK was missed in this previous study in which
pJNK expression was examined 1 week after nerve injury. JNK
activation in DRG neurons was more rapid than that of other
MAPKs, becomingmaximalwithin 12 h. As summarized inTable
1, the cell type expressing pJNK in the DRG is different from that
expressing pERK and p-p38 after nerve injury. JNKwas primarily
activated in unmyelinated C-type neurons in the L5 DRG. Perfu-
sion of the L5 DRG with D-JNKI-1 before nerve injury com-
pletely prevented SNL-inducedmechanical allodynia, suggesting
that JNK activation in C-type neurons in the L5 DRG is essential
for the generation/development of mechanical allodynia. It re-
mains to be investigated how JNK activation in small DRG neu-
rons results in the generation of neuropathic pain. JNK may be
involved in altered gene expression in the injured DRG neurons
after nerve injury (Hokfelt et al., 1994; Ji and Strichartz, 2004).
However, perfusion of D-JNKI-1 in the L5 DRG, starting 10 d
after SNL, did not affect established allodynia. Consistently, JNK
activation in the L5 DRG had significantly declined by day 10.
Therefore, JNK activation in primary sensory neurons appears to
be involved in the development but not the maintenance of neu-
ropathic pain.
SNL also induced c-Jun phosphorylation in most neurons of
the L5 DRG. Therefore, p-c-Jun can be used as a marker for the
injuredDRGneurons. However, pJNK is not amarker for overall
axonal injury, because pJNK is only induced in 35% neurons of
the L5DRGwith small size. Instead, pJNK is specifically related to
C-fiber nociceptors.
Spinal astrocytes and neuropathic pain
Because (1) mechanical allodynia is reversed by intrathecal but
not DRG (L5) perfusion of D-JNKI-1 and (2) JNK activation in
the spinal cord is persistent, we conclude that JNK activation in
the spinal cord contributes to the persistence of neuropathic
pain. Our results also indicate an important role of spinal astro-
cytes in the maintenance of chronic mechanical allodynia. The
importance of spinal astrocytes for persistent pain is further sup-
ported by our data showing that intrathecal injection of the as-
troglial toxin L--aminoadipate could effectively reverse me-
chanical allodynia. The effects of the toxin appear to be specific,
because it only reduces the number of GFAP-expressing astro-
Figure 10. a, b, Perfusion of the L5 DRG with D-JNKI-1 prevents but does not reverse me-
chanical allodynia after SNL. Thepeptide JNK inhibitor D-JNKI-1 (50M)was infused into the L5
DRG via an osmotic pump (0.5l/h), starting 30min before (a) or 10 d after (b) SNL. *p 0.05
by t test compared with corresponding vehicle controls (saline); n 5.
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cytes, associated with a decrease in JNK1 expression, but not of
NeuN-expressing neurons. Because basal pain sensitivity is not
affected by this toxin, spinal astrocytes may not be important for
normal pain perception. Interestingly, the effect of the toxin is
reversible: neuropathic pain returns after 3 d. This reversal may
be attributable to migration of astrocytes from other sites (Khur-
gel et al., 1996; Rodriguez et al., 2004).
Although increasing evidence suggests
that spinal glia play an important role in
pain control (Watkins et al., 2001; Ji and
Strichartz, 2004; Tsuda et al., 2005), to our
knowledge this is the first study that spe-
cifically addresses the role of spinal astro-
cytes in pain sensitization. The role of as-
trocytes in persistent pain is also
supported by the following studies. First,
spinal inhibition of ERK at a late time
point, when pERK is expressed in spinal
astrocytes, attenuates neuropathic pain
(Zhuang et al., 2005). Second, implanta-
tion of neural stem cells into the injured
spinal cord produces astrocytes and is fol-
lowed by the development of mechanical
allodynia (Hofstetter et al., 2005).
Although GFAP upregulation is one of
the most distinct and persistent spinal
changes in chronic pain conditions (Man-
tyh et al., 2002; DeLeo et al., 2004) and has
been correlated with neuropathic pain
(Garrison et al., 1994), we have shown that
neuropathic pain can be blocked by
D-JNKI-1 without accompanying reduc-
tion of GFAP expression. Our data suggest
that spinal GFAP upregulationmay be just
associated with nerve injury but not a
cause for neuropathic pain. Therefore, it
could be misleading to use spinal GFAP
change as an indicator of elevated pain
states. It is the change of signaling mole-
cules, not structural proteins, in astrocytes
that is important for pain sensitization.
It remains to be investigated how JNK
activation in spinal astroglia regulates pain
hypersensitivity. Because D-JNKI-1 sup-
pressed SNL-induced c-Jun phosphoryla-
tion in spinal astrocytes, JNK activation is
likely to regulate gene transcription in spinal astrocytes via acti-
vation of the transcription factor c-Jun, as well as other transcrip-
tion factors such as nuclear factor-B and activating transcrip-
tion factor-2. As a result, there is increased synthesis of
neuroexcitatory and neurosensitizing substances (e.g., BDNF,
IL-1, TNF-, PGE2, etc.) by spinal glia, leading to dorsal horn
Figure 11. a–g, Astroglial toxin L--AA blocks neuropathic pain. a, L--AA (10, 50, and 150 nmol) was injected intrathecally
at 10 d after SNL and reversed mechanical allodynia. *p 0.05, **p 0.01 by ANOVA compared with vehicle (saline) control;
n 6.b–g, Effects of L--AA (50 nmol) on GFAP (b, c), JNK1 (d, e), andNeuN (f,g) expressing cells in the superficial dorsal horn.
Animals with SNL were perfused 24 h after the toxin injection for immunostaining. Scale bar, 50m.
Table 1. Summary of different activation patterns of three MAPK family members (ERK, p38, and JNK) in the DRG and spinal cord in normal and nerve injury
(SNL) conditions
Dorsal root ganglion Spinal cord dorsal horn (gray matter)
Basal expression Injured (L5) Noninjured (L4) Basal expression 3 d 21 d
pERK Small neurons () Large neurons () No significant change Not detectable Microglia () Astrocytes ()
Satellite cells () Satellite cells ()
p-p38 Small neurons () Small neurons () Small neurons () Microglia () Microglia () Microglia ()
Satellite cells () Large neurons () Large neurons ()
pJNK Small neurons () Small neurons () No significant change Astrocytes () Astrocytes () Astrocytes ()
Nerve fibers () Nerve fibers ()
Satellite cells ()
Activation of MAPK is revealed by the expression of pMAPK. There is a low-level, basal expression of pMAPK in normal non-injured condition.,, and indicate low, medium, and high levels of expression of
pMAPK, respectively. Small and large neurons of the DRG are described as NF-200-negative (C-fiber) and NF-200-positive (A-fiber) neurons, respectively. Switch of MAPKs to different cell types at late times has not been clearly studied in
theDRG. pERK is also transiently induced in dorsal hornneurons in the first several hours of nerve injury. See the related references of Kimet al., 2002; Jin et al., 2003; Obata et al., 2003, 2004a,b; Schafers et al., 2003; Tsuda et al., 2004; Zhuang
et al., 2005.
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neuron sensitization (Samad et al., 2001; Watkins et al., 2001;
DeLeo et al., 2004; Ji and Strichartz, 2004; Coull et al., 2005;
Tsuda et al., 2005).
Concluding remarks
This study has identified the JNK cascade as a critical signaling
pathway for neuropathic pain development andmaintenance via
distinct mechanisms in the DRG and spinal cord. In particular,
we have shown that spinal astrocytes play an important role in
maintaining persistent mechanical allodynia, although the un-
derlying mechanisms remain to be investigated.
Many patients in the pain clinic suffer from neuropathic pain
caused by injury to the peripheral nervous system or the CNS,
and one of the most distinct symptoms is mechanical allodynia.
At present, few drugs are effective in treating neuropathic pain,
and their efficacy is only demonstrated in 30% of patients
(Woolf and Mannion, 1999; Gardell et al., 2003). However, all
current drugs were developed or considered to act againstmolec-
ular targets in neurons. Targeting the JNK pathway in spinal glia
and sensory neurons may offer a new option to treat intractable
neuropathic pain.
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